Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-17-021477

Chief Executive Officer sold 18,470 shares at an average $20.76 ($383,393)

  • Chief Executive Officer acquired 3,853 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Novak Rodger · Chief Executive Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2017-08-31 Sale : show line 1 in the form −14,617 $20.87 $305,073 1,148,007 D
2017-09-05 Exercise or conversion : show line 2 in the form +3,853 $1.81 $6,974 1,151,860 D
2017-09-05 Sale : show line 3 in the form −3,853 $20.33 $78,320 1,148,007 D
Open-market sales · 18,470 sh · avg $20.76 · $383,393

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2017-09-05 Exercise or conversion : show line 4 in the form Stock Options (Right to Buy) −3,853 40,826 D
Loading xslF345X03/doc4.xml…